Journals / Türk Kardiyoloji Derneği Arşivi / 2012 / Cilt: 40 - Sayı: 6

Dosetaksel, sisplatin ve 5-florurasil tedavisi sırasında oluşan akut perikardit

Acute pericarditis during 5-fluorouracil, docetaxel and cisplatin therapy

Pages
532–535
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The best method to prevent recurrent pericarditis induced by DCF is to use an alternate chemotherapeutic regimen.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:DCF chemotherapy regimen includes docetaxel, cisplatin, and 5-fluorouracil (5-FU).
📊
Key Findings & Data:Cardiotoxicity is one of the well-known side effects of 5-FU, docetaxel, and cisplatin.
💡
Conclusion & Impact:The best method to prevent recurrent pericarditis induced by DCF is to use an alternate chemotherapeutic regimen.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

DCF chemotherapy regimen includes docetaxel, cisplatin, and 5-fluorouracil (5-FU). Cardiotoxicity is one of the well-known side effects of 5-FU, docetaxel, and cisplatin. In addition, the complications and side effects are more apparent when these three agents are given in combination. For the first time we describe a case of acute pericarditis associated with DCF regimen in a male patient. A 55-year-old man recently diagnosed with syncrone nasopharenx and nonsmall cell lung carcinoma was admitted to the oncology unit for chemotherapy. On the fourth day of infusion therapy with DCF he developed a central chest pain that was in pleuritic character and aggravated by recumbence. On electrocardiography (ECG), there was ST elevation on V2-6, D1, D2, and AVL. The patient was immediately transported to the cardiac catheterization laboratory for primary percutaneous coronary intervention. On coronary angiography, coronary arteries were normal. There was no segmentary wall motion abnormality on left ventricle in transthoracic echocardiography. The patient was diagnosed with acute pericarditis and the DCF regimen was discontinued. After 3 days, chest pain disappeared and ECG was normalized. According to the present case, the management of DCF-induced pericarditis includes stopping the drug and administering supportive treatment. The best method to prevent recurrent pericarditis induced by DCF is to use an alternate chemotherapeutic regimen.

Özet

DCF kemoterapi rejimi dosetaksel, sisplatin ve 5-florurasil (5-FU) ilaçlarını içermektedir. Kardiyotoksisite 5-FU, dosetaksel ve sisplatin tedavisinin bilinen yan etkilerinden biridir. Ayrıca, kardiyotoksisite bu üç ilacın kombine kullanımıyla daha fazla görülebilmektedir. Bu yazıda, ilk defa bir erkek hastada DCF rejimi ile ilişkili akut perikardit olgusu sunuldu. Aynı anda nazofarenks ve küçük hücreli dışı akciğer kanseri tanısı konulmuş 55 yaşında erkek hasta onkoloji kliniğine kemoterapi tedavisi için başvurdu. DCF tedavisinin 4. gününde sırt üstü yatmakla artan ve plöretik tarzda göğüs ağrısı meydana geldi. Çekilen elektrokardiyografide (EKG) V2-6,D1, D2 ve AVL derivasyonlarında ST yükselmesi saptandı. Hasta hemen primer perkütan koroner girişim amacıyla kardiyak kateterizasyon laboratuvarına alındı. Yapılan koroner anjiyografide, koroner arterler normal olarak bulundu. Transtorasik ekokardiyografide sol ventrikül segmenter duvar hareket bozukluğu izlenmedi. Hastaya akut perikardit tanısı konuldu ve DCF tedavisi durduruldu. Üç gün sonra hastanın göğüs ağrısı yakınması kayboldu ve EKG normale döndü. Sunulan olguyla, DCF rejimi ile ilişkili akut perikardit tedavisinin ilaç kesilmesi ve destek tedavisini içerdiğini bildirmekteyiz. DCF ilişkili perikarditin tekrarlamasının önlenmesi için en iyi yol ise uygun başka bir kemoterapi rejimine geçilmesidir.

🔖

Cite This Article

İNANÇ, M., KAYA, G. M., AKPEK, M., İNANÇ, M. T. (2022). Dosetaksel, sisplatin ve 5-florurasil tedavisi sırasında oluşan akut perikardit. Türk Kardiyoloji Derneği Arşivi, Cilt: 40 - Sayı: 6, 532–535. https://ajindex.com/articles/632991

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Aran M, Bilge N, Ozman M. 5-Fluorouracil in the treatment of gastrointestinal tumors. Turk Tip Dernegi Derg 1973;39:459- 65. 2. de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795-801
  2. Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995;49:282-3
  3. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11
  4. Schöber C, Papageorgiou E, Harstrick A, Bokemeyer C, Mügge A, Stahl M, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72:2242-7
  5. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993;71:493-509
  6. Coronel B, Madonna O, Mercatello A, Caillette A, Moskovtchenko JF. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med 1988;14:429-30
  7. Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol 2010;27:680-4
  8. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31
  9. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181-91.